

# A clinical study to evaluate the effects of a fat cell targeted gel for body skin laxity

<b>Submission date</b> 09/02/2026	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 13/02/2026	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 21/05/2026	<b>Condition category</b> Skin and Connective Tissue Diseases	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Plain English summary of protocol not provided at time of registration

## Contact information

### Type(s)

Public, Scientific, Principal investigator

### Contact name

Mr Ivan Galanin

### ORCID ID

<https://orcid.org/0000-0002-8991-9552>

### Contact details

8 East 96th Street  
New York  
United States of America  
10128  
+1 718-750-1492  
ivan@adipeau.com

## Additional identifiers

## Study information

### Scientific Title

A clinical study to validate the laxity reduction effects of a dual-acting lipolytic/adipogenic gel

### Study objectives

This study will evaluate whether a gel that improves the fitness of skin fat cells can improve the appearance of weak skin on the legs and buttocks. The study aims to demonstrate improvement in laxity severity at Week 12 compared to baseline.

**Ethics approval required**

Ethics approval not required

**Ethics approval(s)****Primary study design**

Interventional

**Allocation**

N/A: single arm study

**Masking**

Open (masking not used)

**Control**

Uncontrolled

**Assignment**

Single

**Purpose**

Treatment

**Study type(s)****Health condition(s) or problem(s) studied**

Healthy adults

**Interventions**

Strength Gel (Adipeau Inc), a marketed topical cosmetic containing Kaempferia Parviflora Extract as an active ingredient, was applied by participants 2x per day in a thin layer to areas of skin laxity.

**Intervention Type**

Other

**Primary outcome(s)**

1. Laxity severity measured using the Laxity Scale at baseline and 3 months

**Key secondary outcome(s)**

1. Objective skin texture measurement measured using selected outputs of Antera 3D imaging (e.g., skin texture, large wrinkles, dimpling, elevations) at baseline and 3 months

**Completion date**

14/08/2026

## Eligibility

### Key inclusion criteria

Moderate to severe skin laxity on the legs and/or buttocks.

### Healthy volunteers allowed

Yes

### Age group

Mixed

### Lower age limit

45 years

### Upper age limit

75 years

### Sex

Female

### Total final enrolment

35

### Key exclusion criteria

Anticipated changes to body composition through new exercise regimens, weight loss or major lifestyle changes.

### Date of first enrolment

13/02/2026

### Date of final enrolment

25/06/2026

## Locations

### Countries of recruitment

Australia

United States of America

### Study participating centre

**Ageless Aesthetics by HB Walsh**

Pelican Drive, Suite 2

Bayville

United States of America

08721

**Study participating centre**  
**South County Microspa**  
195 Montana Del Lago Drive  
Rancho Santa Margarita  
United States of America  
92688

**Study participating centre**  
**Advanced Skin by Summer**  
50 Tallis Drive  
Mornington  
Australia  
3931

**Study participating centre**  
**Oasis Haven**  
3151 Airway Avenue, Suite F107  
Costa Mesa  
United States of America  
CA 92626

**Study participating centre**  
**Non-Surgical Youth & Beauty Clinique**  
723 Virginia Dr  
Orlando  
United States of America  
FL 32803

## **Sponsor information**

**Organisation**  
Adipeau Inc.

## **Funder(s)**

**Funder type**

**Funder Name**

Adipeau Inc.

**Results and Publications****Individual participant data (IPD) sharing plan**

All de-identified cropped images used in the analysis of efficacy endpoints to be made available to researchers.

**IPD sharing plan summary**

Available on request